SCHEMBL1897113

SCHEMBL1897113

O=CCc1ccc(Br)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.47
ALOX15 P16050 2/20 0.40
HPGD P15428 2/20 0.39
CASP1 P29466 2/20 0.39
CES2 O00748 1/20 0.39
GALR3 O60755 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALOX12 P18054 3/20 0.38
BCL2 P10415 1/20 0.37
MCL1 Q07820 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
CA12 O43570 2/20 0.36
CA9 Q16790 2/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
TSHR P16473 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789209 0.84 ERN1 (0.52) ERN1ALOX15HPGDCASP1CES2
SCHEMBL15660236 0.81 ERN1 (0.44) ERN1ALOX15HPGDCASP1CES2
SCHEMBL8205 0.80 PDPK1 (0.43)
SCHEMBL472482 0.80 GABRA1 (0.50) ERN1ALOX15HPGDALOX12ALDH1A1
SCHEMBL5738944 0.79 HSP90AA1 (0.41) ERN1ALOX15HPGDALDH1A1TSHR
SCHEMBL933119 0.79 TYR (0.58) ALOX15ALDH1A1HTTTSHRGFER
SCHEMBL30513627 0.79 TYR (0.58) ALOX15ALDH1A1HTTTSHRGFER
SCHEMBL6739825 0.78 KDM4E (0.38) ERN1ALOX15ALDH1A1
SCHEMBL1569775 0.78 CA3 (0.46) ALOX15HTTCA9TYR
SCHEMBL4573203 0.77 ALOX15 (0.38) ERN1ALOX15HPGDCASP1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112218872-B Tungsten (VI) compounds with thermally activated delayed fluorescence or phosphorescence for organic light emitting devices 香港大学 2023-11-03 CN claimed
US-20210380616-A1 TUNGSTEN (VI) COMPOUNDS WITH THERMALLY ACTIVATED DELAYED FLUORESCENCE OR PHOSPHORESCENCE FOR ORGANIC LIGHT-EMITTING DEVICES THE UNIVERSITY OF HONG KONG (CN) 2021-12-09 US claimed
CN-112218872-A Tungsten (VI) compounds with thermally activated delayed fluorescence or phosphorescence for organic light emitting devices 香港大学 2021-01-12 CN claimed
WO-2019228512-A1 TUNGSTEN (VI) COMPOUNDS WITH THERMALLY ACTIVATED DELAYED FLUORESCENCE OR PHOSPHORESCENCE FOR ORGANIC LIGHT-EMITTING DEVICES THE UNIVERSITY OF HONG KONG (CN) 2019-12-05 WO claimed
WO-2024025953-A2 THERAPEUTIC USES OF UROLITHIN DERIVATIVES VANDRIA SA (CH) 2024-02-01 WO disclosed
EP-3790865-A1 PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT Janssen Pharmaceutica NV (BE) 2021-03-17 EP disclosed
EP-3774777-A2 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
EP-3774789-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
WO-2019243999-A1 PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
EP-3365061-A1 AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS Axovant Sciences GmbH (DE) 2018-08-29 EP disclosed
WO-2018102554-A1 CLEAVABLE NUCLEOTIDE ANALOGS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-06-07 WO disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO disclosed
WO-2010019905-A1 NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS N30 PHARMACEUTICALS, LLC (US) 2010-02-18 WO disclosed
WO-2009102633-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 WO disclosed
WO-2009039127-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C ABBOTT LABORATORIES (US) 2009-03-26 WO disclosed
WO-2009039134-A1 ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF ABBOTT LABORATORIES (US) 2009-03-26 WO disclosed
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 WO disclosed
EP-0918768-A1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C Research Laboratories (KR) 1999-06-02 EP disclosed
WO-1997045424-A1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C RESEARCH LABORATORIES (KR) 1997-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380616-A1 TUNGSTEN (VI) COMPOUNDS WITH THERMALLY ACTIVATED DELAYED FLUORESCENCE OR PHOSPHORESCENCE FOR ORGANIC LIGHT-EMITTING DEVICES OCIAD2, TRPC6, NUDT1 ERN1 2456/4885ALOX15 1285/4885HPGD 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.